Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany To Tackle Cell And Gene Therapy Funding Barriers

Executive Summary

If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.

You may also be interested in...



Market Access Lessons For Cell And Gene Therapies In Germany

Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.

Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing

The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.

Europe’s Biggest Multi-Country Access Alliance Picks Up The Pace

The Valletta Group says that cancer drugs, treatments for autoimmune diseases, orphan medicines and biosimilars are among the products it is targeting in its joint procurement efforts.

Topics

UsernamePublicRestriction

Register

PS144498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel